ClinicalTrials.gg
DrugBiological

Dinutuximab clinical trials

Also written Ch14.18, Unituxin and Qarziba.

studies test it
35
open now
12
in phase 3
8
first study started
2001

How each study uses dinutuximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the dinutuximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
10 Mar 2015 · UNITUXIN · BLA 125516 (FDA, Drugs@FDA)
European Union
14 Aug 2015 · Unituxin · EMEA/H/C/002800 (EMA; now withdrawn)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Dinutuximab Beta
17
Dinutuximab
15
MOAB Ch14.18
10
monoclonal antibody Ch14.18
10
Ch 14.18UTC
9

Brand

Unituxin
14
Qarziba
11

Development codes

Ch14.18
17

Studies by the year they started

35 studies that test it; most in 2022 (4)

Studies that test dinutuximab, by start year
YearStudies
20012
20021
20051
20091
20101
20121
20133
20141
20151
20161
20171
20181
20193
20201
20213
20224
20231
20243
20252
20263

By phase

A phase 1/2 study counts in both.

Phase 1
13
Phase 2
19
Phase 3
8

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 32

National Cancer Institute (NCI) (9) · New Approaches to Neuroblastoma Therapy Consortium (4) · University of Birmingham (2) · United Therapeutics (2) · St. Anna Kinderkrebsforschung (2) · Children's Hospital Los Angeles (1) · Nationwide Children's Hospital (1) · Children's Oncology Group (1)

Often tested with

Tested in the same studies.

Irinotecan (8) · Temozolomide (6) · Isotretinoin (3) · Natural Killer Cell (3) · Sargramostim (3) · Granulocyte-Macrophage Colony-Stimulating Factor (3) · Lenalidomide (2) · Bevacizumab (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 5, 2 in phase 3

Studies that test dinutuximab, phase 3 first.

Studies

Open first, then newest update. How each study uses dinutuximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 35

See all 35 studies that test dinutuximab →

Given beside what is tested · 8 — dinutuximab is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call dinutuximab · ClinicalTrials.gg INT004079

  • MeSH (NLM) C112746dinutuximabConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 7SQY4ZUD30DINUTUXIMABConfirmed FDA, NLM, Wikidata
  • RxNorm 1606274Confirmed FDA, Wikidata
  • Wikidata Q21011236dinutuximabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C1570DinutuximabOne source FDA
  • DrugBank DB09077One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.